Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.675
Bid: 1.65
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.05 (3.03%)
Open: 1.675
High: 1.725
Low: 1.625
Prev. Close: 1.675
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Apr 2010 09:42

RNS Number : 1189L
Epistem Holdings plc
30 April 2010
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Epistem Holdings plc

 

 

 

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

Octopus Investments Nominees Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

16/04/10

6. Date on which issuer notified:

29/04/10

7. Threshold(s) that is/are crossed or reached: vi, vii

4%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B1VKB244

 

364300

 

364300

 

315000

 

315000

 

3.97%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

315000

 

3.97%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Russell Jarvis

15. Contact telephone number:

020 7710 8653

 

Note: Annex should only be submitted to the FSA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Peter Orsi

Contact address

(registered office for legal entities)

 

8 Angel Court, London, EC2R 7HP

Phone number & email

 

020 7710 8653

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Contact address

 

Phone number & email

 

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUROWRRWASORR
Date   Source Headline
24th Aug 20187:00 amRNSNotice of GM
22nd Aug 20187:00 amRNSBoard Appointment
8th Aug 20187:00 amRNSgenedrive partners with FIND to evaluate HCV test
19th Jul 20187:00 amRNSDirector/PDMR Shareholding
13th Jul 20187:00 amRNSTrading Update
29th Jun 20189:36 amRNSTotal Voting Rights
27th Jun 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Preventing hearing loss in newborns
20th Jun 20187:00 amRNSGrant for NHS point-of-care test
19th Jun 201811:18 amRNSAdditional Listing of Shares
11th Jun 20189:25 amRNSCompletion of Disposal
4th Jun 20184:47 pmRNSResult of General Meeting
17th May 20182:32 pmRNSCircular re Proposed Disposal
14th May 20185:39 pmRNSProposed disposal for up to £1.9 million in cash
10th May 201811:39 amRNSHolding(s) in Company
18th Apr 20187:00 amRNSgenedrive plc to Present at the UK Investor Show
12th Apr 20189:53 amEQSHardman & Co Research: genedrive plc (GDR): Progressing commercialisation plans
10th Apr 20187:00 amRNSPublication of Genedrive Performance Data in Gut
9th Apr 20189:06 amRNSDirectorate Change
4th Apr 20188:48 amRNSDirector/PDMR Shareholding
3rd Apr 20187:00 amRNSGenedrive® Hepatitis C test in Asia Pacific
27th Mar 20187:00 amRNSgenedrive signs distribution agreement for India
20th Mar 20183:40 pmRNSHolding(s) in Company
20th Mar 20187:00 amRNSInterim Results
13th Mar 20187:00 amRNSCommercial sales of Genedrive® HCV ID Kit begin
27th Feb 20187:00 amRNSgenedrive Receives Funding for TB Test Development
14th Feb 20187:00 amRNSNotice of Results
18th Jan 201811:59 amRNSHardman Res: Hep-C point-of-care test launched
17th Jan 20182:01 pmRNSHolding(s) in Company
17th Jan 20187:00 amRNSTrading update
16th Jan 20187:00 amRNSFirst Successful Field Evaluation of HCV Assay
13th Dec 20177:15 amRNSHardman Research: Remodelled for growth
7th Dec 20174:28 pmRNSDirector/PDMR Shareholding
29th Nov 20172:19 pmRNSResult of AGM
21st Nov 20177:00 amRNSgenedrive plc awarded Innovate UK grant
17th Nov 201711:25 amRNS2017 Annual Report and AGM Notice
14th Nov 20177:00 amRNSDistribution agreement with Sysmex Asia Pacific
8th Nov 20171:31 pmRNSDirectorate Change
6th Nov 20178:51 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSDistribution update for India
23rd Oct 20177:00 amRNSLaunches Genedrive® Hepatitis C test in Africa
18th Oct 20177:00 amRNSHolding(s) in Company
17th Oct 20177:00 amRNSPreliminary Results
16th Oct 20177:00 amRNSDistribution Agreement
11th Oct 20177:00 amRNSNotice of Preliminary Results
22nd Sep 20179:42 amRNSHolding(s) in Company
11th Sep 20177:00 amRNSGenedrive HCV Kit received CE Marking
27th Jul 20177:00 amRNS$1.4m Funding from US Department of Defense
13th Jul 20177:00 amRNSTrading Update
11th Apr 20177:00 amRNSHep C data presentation at EASL
5th Apr 201712:39 pmRNSDirector/PDMR Shareholding - Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.